Document is current
Any future updates will be listed below
-
Authors
Skals, Marianne https://orcid.org/0000-0001-9420-5143
Broch-Lips, Martin https://orcid.org/0000-0002-8962-2505
Skov, Martin Brandhøj https://orcid.org/0000-0003-4449-472X
Riisager, Anders
Ceelen, Judith
Nielsen, Ole Bækgaard
Brull, Sorin J. https://orcid.org/0000-0003-2607-2590
de Boer, Hans D. https://orcid.org/0000-0002-0490-2074
Pedersen, Thomas Holm https://orcid.org/0000-0002-1060-4989
-
Funding
Funding for this research was provided by:
Innovationsfonden (0174-00051A)
- License Information
-
More Information
Article History
Received: 3 April 2024
Accepted: 4 October 2024
First Online: 28 October 2024
Competing interests
: The studies were sponsored by NMD Pharma. Marianne Skals, Martin Broch-Lips, Martin Brandhøj Skov, Anders Riisager, Judith Ceelen, Ole Bækgaard Nielsen and Thomas Holm Pedersen were or are employed by NMD Pharma A/S and may own and/or hold options/restricted stock units for the company and/or patents on the designed compounds. Hans D. de Boer is member of the Global Advisory Board of Merck & Co. (Kenilworth, NJ, USA), member of the Scientific Advisory Board of Senzime (Uppsala, Sweden), member of the Global Advisory Board of NMD Pharma (Aarhus, Denmark), Chairman of the Dutch Society for Enhanced Recovery After Surgery and founder of ERASNextGen®. Sorin J. Brull has intellectual property assigned to Mayo Clinic (Rochester, MN); was a consultant for Merck & Co., Inc. (Kenilworth, NJ, USA); is a principal, shareholder and Chief Medical Officer in Senzime AB (publ) (Uppsala, Sweden); and an unpaid member of the Scientific/Clinical Advisory Boards for Coala Life Inc. (Irvine, CA); NMD Pharma (Aarhus, Denmark); and Takeda Pharmaceuticals (Cambridge, MA). The authors declare no other competing interest.
